Bioglutide NA-931

NA-931 (Bioglutide ™): for the treatment of obesity
NA-931 (Bioglutide ™) has been shown to demonstrate a proof of efficacy and safety for potential treatment of obesity and alcohol use disorder.

Obesity is a medical condition, sometimes considered a disease, in which excess body fat has accumulated to such an extent that it can potentially have negative effects on health. People are classified as obese when their body mass index (BMI)—a person’s weight divided by the square of the person’s height—is over 30 kg/m2; the range 25–30 kg/m2 is defined as overweight.

Obesity is a major cause of disability and is correlated with various diseases and conditions, particularly cardiovascular diseases, type 2 diabetes, obstructive sleep apnea, certain types of cancer, and osteoarthritis.

Obesity is associated with the impairment of normal GH (growth hormone), GLP-1 secretion, and responses to all stimuli such as GH-releasing hormone (GHRH), hypoglycaemia, L-dopa, arginine, glucagon, physical exercise, and sleep.

Glucagon-like peptide-1 (GLP-1) is an endogenous gut hormone and a key regulator in maintaining glucose homeostasis by stimulating insulin secretion.

NA-931 (Bioglutide ™): the first Quadruple Action of four major hormones receptors/agonists of IGF-1, GLP-1, GIP and Glucagon

NA-931 (Bioglutide ™) has been developed for chronic weight management in adults with a body mass index (BMI) of 30 kg/m² or greater (obesity) or 27 kg/m² or greater (overweight) with at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease).

Press release Biomed Industries, Inc. to Present a New Quadruple Agonist for Weight Loss at American Diabetes Association and Euro Obesity Conference in June 2024

Press release Biomed Industries, Inc. to announced the Phase 1 clinial results of its quadruple receptor agonist NA-931 for the treatment of obesity

Press release Biomed presented its quadruple agonist NA-931 at the World Obesity Congress, October 24-26, 2024 in Baltimore, Maryland, USA

How does it work?

NA-931™ (Bioglutide ™), a quadruple receptor agonist, has demonstrated a proof of efficacy and safety for potential treatment of obesity. NA-931 regulates the homeostasis of IGF-1, GLP-1, GIP and Glucagon to facilitate weight loss without many of the adverse events associated with current obesity drugs.

NA-931 (Bioglutide ™) can easily cross the blood brain barrier, so only a small dose of the drug is required to be effective. The drug shows the following properties:

* NA-931 regulates IGF-1, GLP-1 and GIP and Glucagon

* It has great bioavailability in the body

* It is safe and well tolerated, with no serious adverse events observed

* It has been shown to significantly reduce the body mass index, without muscle loss

* It is available in oral formulation: convenient for patient to take one capsule once a day.

NA-931 (Bioglutide ™) is in Phase 2B clinical trials. NA-931 not only significantly reduces body fat but also preserves muscle mass. Furthermore, NA-931 exhibits a notable reduction in adverse events commonly associated with existing treatments.

“Phase 2 Trials of NA-931 to Study Subjects Who Are Obese With at Least One Weight-related Comorbid Condition” has been posted on https://clinicaltrials.gov of the National Institute of Health, USA
(ClinicalTrials.gov ID NCT06564753)

“Phase 2 on Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese”
ClinicalTrials.gov ID NCT06732245